Kaken Pharmaceutical Co., Ltd. 4521
TSE · Japan · Health Technology
¥3,775.00-60.00 (-1.56%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
How Kaken Pharmaceutical’s Recent Performance Frames the Investment Question Kaken Pharmaceutical (TSE:4521) has drawn attention after recent share price moves, with a 1 day return of 1.08%, a flat week, a small decline over the past month, and a modest gain over the past 3 months. See our latest analysis for Kaken Pharmaceutical. At the current share price of ¥4,220, Kaken Pharmaceutical’s modest 3 month share price return of 2.30% sits alongside a year to date share price return of 5.11%...
Moby summary of KalVista Pharmaceuticals, Inc.'s Q1 2025 earnings call
Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinicHORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, and Kaken Pharmaceutical Co., Ltd. (“Kaken”), an R&D driven pharmaceutical company in Japan, today announced a strategic licensing and co-development agreement fo
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.